AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue

▤ Summary

AlzeCure Pharma secured additional subscription commitments of about SEK 7 million for its ongoing rights issue. The new commitments come from qualified investors and raise total committed subscriptions to about SEK 32 million, or roughly 66% of the planned SEK 48.5 million issue. The company plans to use the proceeds mainly to prepare for a Phase 2 study in Alzheimer’s patients with NeuroRestore ACD856. AlzeCure also noted support from investors as validation of the project and confirmed the subscription period runs through July 22.

$ Funding

▦ Linked Companies